Video

Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Bispecific monoclonal antibodies were a big focus of research at the 2019 ASH Annual Meeting, says Kaplan, most of which target CD3 and CD20. Not only were these agents active in aggressive B-cell lymphomas, but they appear to have significant response rates in indolent B-cell lymphomas as well, including in patients who recur after CAR T-cell therapy.

Many of these studies have limited follow-up. However, these agents are expected to be a lot easier to administer in the outpatient setting with somewhat less toxicity than CAR T-cell therapy, says Kaplan. As a result, these agents may become more widely available to the patient populations who need them, Kaplan concludes.

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD